Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25445624 | 0.92 | PDK2 (0.32) | PDK2MCL1 | |
| SCHEMBL25444650 | 0.87 | MCL1 (0.38) | PDK2MCL1MAP4K4FDPSPTPN5 | |
| SCHEMBL25445532 | 0.87 | MCL1 (0.38) | PDK2MCL1MAP4K4FDPSPTPN5 | |
| SCHEMBL25445656 | 0.87 | MCL1 (0.34) | PDK2MCL1MAP4K4FDPS | |
| SCHEMBL25445453 | 0.86 | MAP4K4 (0.38) | PDK2MCL1MAP4K4FDPSPTPN5 | |
| SCHEMBL25445903 | 0.83 | PDK2 (0.38) | PDK2MCL1MAP4K4TP53MAPT | |
| SCHEMBL25444671 | 0.83 | PDK2 (0.31) | PDK2MCL1 | |
| SCHEMBL25445501 | 0.82 | MCL1 (0.35) | PDK2MCL1MAP4K4FDPSTP53 | |
| SCHEMBL25444741 | 0.79 | PDK2 (0.38) | PDK2 | |
| SCHEMBL25445892 | 0.78 | PDK2 (0.44) | PDK2MCL1MAP4K4ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143779-A1 | ORGANIC SOLID-STATE LASER, COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230143779-A1 | ORGANIC SOLID-STATE LASER, COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143779-A1 | ORGANIC SOLID-STATE LASER, COMPOUND AND USE THEREOF | LEF1, CCNT1, CCNT2 | PDK2 3407/4885MCL1 1322/4885MAP4K4 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.